About the Study

ARO 013 - This is a multicenter, randomized, double-blinded, placebo-controlled, trial of oral crenolanib versus oral placebo in combination with best supportive care in subjects with advanced or metastatic GIST with a D842V mutation in the PDGFRA gene. Approximate

Clinical Site Contact Information

AROG Site 1
3795 Chapel Street, TX
USA

Principal Investigator
Principal Investigator
Margaret von Mehren

margaret.j@gmail.com.test
(718) 907-6754

Book an appointment